Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
_256_384.jpg)
33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Subscribe To Our Newsletter & Stay Updated
